Clinical Advances in Hematology & Oncology最新文献_第10页

Management of Richter transformation. 李氏变换的管理。

IF 1

Clinical Advances in Hematology & Oncology Pub Date : 2023-08-01

Matthew S Davids

引用次数: 0

Neoadjuvant immunotherapy in resectable non-small cell lung cancer. 可切除非小细胞肺癌的新辅助免疫治疗。

IF 1

Clinical Advances in Hematology & Oncology Pub Date : 2023-08-01

Sarah E Lochrin, Patrick M Forde

{"title":"Neoadjuvant immunotherapy in resectable non-small cell lung cancer.","authors":"Sarah E Lochrin, Patrick M Forde","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Lung cancer is the leading cause of cancer-related deaths worldwide and is associated with poor 5-year outcomes, even among the 20% to 25% of patients who present with operable disease. Cisplatin-based adjuvant chemotherapy has long been the standard of care for patients with resected non-small cell lung cancer (NSCLC). With the incorporation of immunotherapy, however, the treatment paradigm for NSCLC has changed dramatically. The introduction of immune checkpoint blockade has improved clinical outcomes in multiple phase 2 and 3 trials in both the neoadjuvant and adjuvant setting, resulting in new US Food and Drug Administration approvals in the management of early-stage resectable lung cancer. This review explores the biological rationale for immune checkpoint blockade, both as monotherapy and in combination with chemotherapy, in conjunction with surgical management of patients with NSCLC. It also highlights the reported clinical trial data that have led to significant advances in the management of early-stage NSCLC. Additionally, this review summarizes ongoing key studies that will provide vital data on the clinical efficacy of these treatment approaches. The outcomes of ongoing trials and the associated biomarker-focused correlative studies will be critical to furthering the mechanistic understanding of immune checkpoint blockade in early-stage NSCLC. This, in turn, will help to uncover biomarkers of response and resistance in these patients.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9929318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjuvant therapy in high-risk, node-negative melanoma. 高危淋巴结阴性黑色素瘤的辅助治疗。

IF 1

Clinical Advances in Hematology & Oncology Pub Date : 2023-08-01

Merrick I Ross

引用次数: 0

Recent approval of pirtobrutinib for mantle cell lymphoma. 最近批准吡托鲁替尼用于套细胞淋巴瘤。

IF 1

Clinical Advances in Hematology & Oncology Pub Date : 2023-08-01

Jonathon B Cohen

引用次数: 0

Updates in small cell lung cancer. 小细胞肺癌的最新进展。